Clinical Trials Logo
  1. Home
  2. ARDS, Human
  3. NCT03215316

Screening Expiratory Flow Limitation by Flow-time Curve — FLOWLY  

ARDS, Human Clinical Trial

Official title:
Screening Expiratory Flow Limitation by Flow-time Curve

Clinical Trial Summary

Expiratory flow limitation (EFL) is defined as a dynamic condition that expiratory flow cannot be further increased with higher expiratory driving pressure. Under mechanical ventilation, it can cause intrinsic positive end-expiratory pressure (PEEP) and dynamic hyperinflation, and be associated with worse clinical outcome. The detection of EFL however needs special maneuvers and offline analysis of flow-volume curves, which are infeasible in routine practice and cannot be used during real-time monitoring. The investigators propose a new and simple approach using flow derived parameters to detect EFL in real time without needing any intervention.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03215316
Study type Observational
Source St. Michael's Hospital, Toronto
Contact Laurent Brochard
Phone 416-864-5686
Email brochardl@smh.ca
Status Recruiting
Phase N/A
Start date September 1, 2017
Completion date September 2019
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06444750 - Comparison of the Proteome in ICU Patients in Search for TRALI Biomarkers
Not yet recruiting NCT05306392 - Effects of Induced Moderate Hypothermia on ARDS Patients Under Venovenous ExtraCorporeal Membrane Oxygenation N/A
Completed NCT04274296 - Advisory Lead ARDS Respirator Management
Completed NCT04719182 - Practice of Adjunctive Treatments in Intensive Care Unit Patients With COVID-19
Terminated NCT04954014 - Pilot Study of Single Dose Bevacizumab as Treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients Phase 2
Recruiting NCT04115514 - Treatment of ARDS With Instilled T3 Phase 2
Not yet recruiting NCT05061212 - The Mechanism of Extracellular Vesicles Containing Mitochondrial DNA in ARDS Lung Injury Caused by Extrapulmonary Sepsis
Completed NCT05693051 - Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
Not yet recruiting NCT04556864 - Hemodynamic Impact on Critical Care Patients With Lung Damage Secondary to COVID-19
Recruiting NCT04174014 - Optimal PEEP Titration Combining Transpulmonary Pressure Measurement and Electric Impedance Tomography N/A
Enrolling by invitation NCT06164639 - Potential Biomarkers for Reflux Aspiration-induced Lung Injury.
Terminated NCT05384379 - Efficacy and Safety Evaluation of BZ371B in ARDS Patients Early Phase 1
Completed NCT04375735 - London's Exogenous Surfactant Study for COVID19 Phase 1/Phase 2
Completed NCT06224010 - Respiratory Drive and Inspiratory Effort in COVID-19 Associated ARDS
Not yet recruiting NCT04530188 - Effects of Sevoflurane on Extravascular Lung Water and Pulmonary Vascular Permeability in Patients With ARDS Phase 3
Completed NCT03405038 - Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization
Recruiting NCT05148026 - Regional Citrate Anticoagulation for RRT During V-V ECMO N/A
Recruiting NCT04390360 - Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction N/A
Completed NCT06197256 - Cardiac Dysfunction in Critically Ill Covid-19 Patients
Completed NCT04008225 - Study of the Effects of Bronchoalveolar Lavage Liquid in the ARDS on the Functioning of the Neutrophil Polynuclear System